Product datasheet for TL320717V

PAK6 Human shRNA Lentiviral Particle (Locus ID 56924)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	PAK6 Human shRNA Lentiviral Particle (Locus ID 56924)
Locus ID:	56924
Synonyms:	PAK5
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	PAK6 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
RefSeq:	NM_001276717, NM_001276718, NM_020168, NM_020168.1, NM_020168.2, NM_020168.3, NM_020168.4, NM_020168.5, NM_001128629.1, NM_001128628.1, NM_001276718.1, NM_001276717.1, BC035596, BC035596.1, NM_001276718.2
UniProt ID:	Q9NQU5
Summary:	This gene encodes a member of a family of p21-stimulated serine/threonine protein kinases, which contain an amino-terminal Cdc42/Rac interactive binding (CRIB) domain and a carboxyl-terminal kinase domain. These kinases function in a number of cellular processes, including cytoskeleton rearrangement, apoptosis, and the mitogen-activated protein (MAP) kinase signaling pathway. The protein encoded by this gene interacts with androgen receptor (AR) and translocates to the nucleus, where it is involved in transcriptional regulation. Changes in expression of this gene have been linked to prostate cancer. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2015]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.

View online »

Performance Guaranteed:	OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).